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Central initiation of plus strand synthesis is a conserved feature of lentiviruses and certain other
retroelements. This complication of the standard reverse transcription mechanism produces a transient
“central DNA ﬂap” in the viral cDNA, which has been proposed to mediate its subsequent nuclear import.
This model has assumed that the important feature is the ﬂapped DNA structure itself rather than the
process that produces it. Recently, an alternative kinetic model was proposed. It posits that central plus
strand synthesis functions to accelerate conversion to the double-stranded state, thereby helping HIV-1
to evade single-strand DNA-targeting antiviral restrictions such as APOBEC3 proteins, and perhaps to
avoid innate immune sensor mechanisms. The model is consistent with evidence that lentiviruses must
often synthesize their cDNAs when dNTP concentrations are limiting and with data linking reverse
transcription and uncoating. There may be additional kinetic advantages for the artiﬁcial genomes of
lentiviral gene therapy vectors.
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Reverse transcription is the process whereby retroviruses and
other retroelements convert their single-stranded RNA genomesll rights reserved.into double-stranded DNA (dsDNA). By integrating the resulting
cDNA and thereby archiving their genomes in a host chromosome
in each replication cycle, retroelements achieve a permanent safe
harbor that is hereditable at the level of the somatic cell or, when
integration occurs in the germline, at the level of the species.
The impact of this chromosomal archiving strategy is reﬂected
in numerous instances, ranging from our inability to eradicate
HIV-1 with antiviral therapy to the vast number of endogenous
E. Poeschla / Virology 441 (2013) 1–112retroviruses and other retroelements that have colonized verte-
brate genomes.
It follows that reverse transcription mechanisms have survived
stringent natural selection for efﬁciency and for resilience in the
face of reciprocal host cell efforts to defend genome integrity.
The basic reaction steps for retroviruses were worked out over 30
years ago. Retroviral reverse transcriptases require a primer to
initiate synthesis. A host cell transfer RNA is used to prime the ﬁrst
(minus) strand DNA. For the plus strand DNA, initiation occurs at
an RNAse H-spared remnant of the genomic RNA (gRNA), the
polypurine tract (PPT, Fig. 1A). This short purine-rich sequence is
positioned at the 3′ end of the viral genome to facilitate synthesis
of the long terminal repeat (LTR) plus strand (Fig. 1A, stage 1).
For the majority of the plus strand to complete, this short DNA
segment must then transfer to template off the 3′ end of the minus
strand (Fig. 1A, transition from stage 2 to 3). The “second jump” or,
more accurately, the second strand transfer is a point of potential
delay in the overall process. It cannot occur and hence completion
of most of the plus strand cannot begin until the minus strand has
extended to the point at which the whole process started, i.e., the
tRNA primer binding site (PBS). At this point, extension of the
majority of the plus strand (and the remaining short stretch ofFig. 1. Retroviral plus strand synthesis. The process is diagramed with (A) and without (B
occur earlier in B. See text for details.
Fig. 2. The cPPT-CTS. Wild type and various mutant sequences used in various studies ar
on black. The cPPT-D mutant (Zennou et al., 2000) was subsequently used in other stud
2002; Limon et al., 2002; Marsden and Zack, 2007; Sirven et al., 2000). The CTS, wher
synthesis (Charneau et al., 1994; Stetor et al., 1999; Whitwam et al., 2001), consists of a s
indicated here by overhead brackets. By comparison, one CA5T2 motif triggers a singleminus strand) can each occur and the viral DNA eventually
becomes fully double-stranded (Fig. 1A, stages 4–5).The discovery of lentiviral central plus strand initiation
In two studies by the Haase laboratory in the 1980s, an interesting
complication arose (Blum et al., 1985; Harris et al., 1981). Working
with the sheep lentivirus Visna prior to the discovery of HIV-1, this
group deduced that Visna cDNAs that had not yet integrated were
linear duplexes consisting of a full-length minus strand and two plus
strands separated by a nick or gap in the center (Harris et al., 1981).
This initial paper established basic facts: the discontinuity, its presence
on the plus strand only, and its intriguing, precisely central location. It
also employed methods such as S1 nuclease digestion that continue to
be useful. The second paper then identiﬁed that the gap has its origin
in a central plus strand initiation step and outlined the basic sequence
of events (Blum et al., 1985), which are diagramed in Fig. 1B.
When the ﬁrst HIV-1 genome sequences were obtained (Ratner
et al., 1985), they revealed an exact copy of the PPT at the center of
the genome (the cPPT), in the integrase reading frame, which was
congruent with the preceding Visna studies. The conservation of) central plus strand initiation. Note that full plus strand completion is predicted to
e shown and referenced. Nucleotide and amino acid changes are highlighted white
ies (Ao et al., 2004; Arhel et al., 2006a; De Rijck and Debyser, 2006; Dvorin et al.,
e the Uþ strand terminates after approximately 90 nt of Dþ strand displacement
tring of CAnTm motifs with terminations clustering at ter1 (CA5T2 ) and ter2 (CA4T4),
termination stop in the FIV CTS (Whitwam et al., 2001).
Fig. 3. cPPT and CTS elements in various retroviruses.
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important role in the life cycle. In the early 1990s, Pierre Charneau
and colleagues at the Institut Pasteur began to characterize the
HIV-1 cPPT and develop models to explain its raison d'être (Charneau
et al., 1992; Charneau and Clavel, 1991). In lowmolecular weight HIV-
1 DNA extracted from infected cells, they identiﬁed a Visna-like
central plus strand discontinuity, and they determined that the 5′ end
of the downstream (Dþ) segment was indeed at the cPPT. Charneau
and colleagues then went on to locate the upstream (Uþ) strand
termination point (Charneau et al., 1994). This central termination
sequence (CTS) turned out to be located in the minus strand DNA
about 90–100 nt downstream of the Dþ strand start (Charneau et al.,
1994). The location of the two termini implies plus strand displace-
ment synthesis, which had previously been recognized to occur in
retroviruses (Boone and Skalka, 1981b), and a triple-stranded central
“ﬂap” in which the redundant 0.1 kb of Dþ strand DNA is unpaired
(Fig. 1B, step 5 & Fig. 2).
There is little evidence that the strand-displaced region is
strongly structured, e.g. by forming a triplex structure. In vitro
modeling based on oligonucleotide migration rates in native
gels suggested a possibility that an intramolecular quadruplex
(a G-quartet) is formed by Hoogsteen base-pairing between G-rich
segments of the overlapping Uþ strand 3′ end and Dþ strand 5′
end (Lyonnais et al., 2003,2002). However, circular dichroism
spectroscopy experiments carried out in the presence and absence
of the viral nucleocapsid protein (NC) provided no evidence for
this or for triplex formation whether or not NC was present.
Instead, a canonical DNA duplex with an unassociated “ﬂapping”
Dþ strand was identiﬁed (Kankia and Musier-Forsyth, 2007).
The CTS consists of a string of CAnTm motifs with HIV-1 termina-
tions clustering at ter1 (CA5T2 ) and ter2 (CA4T4) (Charneau et al.,
1994). Fig. 2 shows the cPPT and CTS elements in HIV-1 along with
several mutants used in various studies. Fig. 3 illustrates the situation
in different retroviruses. After Visna and HIV-1, cPPT and CTS
elements that yield a central ﬂap structure were identiﬁed in FIV
(Whitwam et al., 2001) and EIAV (Stetor et al., 1999), as well as in
spumaretroviruses (Kupiec et al., 1988; Tobaly-Tapiero et al., 1991) and
in the yeast retrotransposon Ty1 (Heyman et al., 1995, 2003; Wilhelm
et al., 1999). Therefore, explanatory models should take into account
that convergent evolution has produced central plus strand initiation
in diverse retroelements. The CTS elements of each of the viruses are
similar in consisting of short poly-A/T runs and each limits the central
plus strand displacement to approximately 0.1 kb. One CA5T2 motif
triggers a dominant single termination in the FIV CTS (Whitwam
et al., 2001) while in EIAV two adjacent termination sites have beenidentiﬁed (Stetor et al., 1999). RT termination is induced in part by A
tracts in these motifs, which have been reported to foster minor
groove compression in the DNA duplex (Klarmann et al., 1993; Stetor
et al., 1999).
An HIV-1 cPPT mutant virus with 4 purine-to-pyrimidine
changes (the 225 mutant, Fig. 2), replicated slowly in two speciﬁc
cell types: peripheral blood mononuclear cells (PBMCs) and the
CD4þ T cell line CEM (Charneau et al., 1992). In contrast, there was
no delay of this mutant in another CD4þ T cell line, MT4
(Charneau et al., 1992). As will be discussed further below, in
retrospect, this cell-speciﬁc difference in the 1992 paper can be
seen as a clue that APOBEC3 protein-mediated restriction might be
a signiﬁcant variable, because PBMCs and CEM cells express
substantial levels of this restriction factor.
In the initial studies, the central plus strand discontinuity was
absent from viral cDNA forms that are identiﬁably nuclear in location
(circularized genomes), which suggested that DNA repair enzymes act
to repair the gap after nuclear import. The precise repair choreogra-
phy remains unknown but linear HIV-1 pre-integration complexes
with plus-strand discontinuities are competent to integrate in vitro
(Miller et al., 1995), suggesting that in the bona ﬁde provirus the
repair can occur after ligation of the LTR 5′ termini to host DNA.
It should also be noted that while the majority of gammaretroviral
cDNA isolated from infected cells contains continuous plus strands,
which is consistent with the standard reverse transcription model
shown in Fig. 1A, discontinuous plus strands with initiations mapping
to locations upstream of the 3′ PPT have also been detected in avian
retroviruses and as minor species in gammaretroviral endogenous
reactions (Boone and Skalka, 1981a,1981b; DesGroseillers et al., 1982;
Hsu and Taylor, 1982; Kung et al., 1981; Rattray and Champoux, 1987;
Taylor et al., 1983; Varmus et al., 1978). The virological advantage this
provides was not clear from these studies and discussion centered for
the most part on promotion of recombination. It is conceivable that a
beneﬁt from accelerated formation of complete proviral DNA may
also underlie these alternative initiations in these retroviruses that do
not infect non-dividing cells. This kinetic theme receives emphasis in
recent work with HIV-1.Two theories of function
Although the topic has seen its fair share of controversy, it is not in
doubt that the cPPT-CTS element is important. This is axiomatic given
its strict conservation in HIV-1 and its convergently evolved usage in
complex retroviruses and retrotransposons. The question is how. Two
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emphasizes the region of triple-stranded DNA itself as a mediator of
pre-integration complex (PIC) nuclear import (Zennou et al., 2000)
and one, the kinetic model, emphasizes the kinetic consequences of
central initiation of plus strand synthesis (Hu et al., 2010). These
models are not mutually exclusive.
The “ﬂap:” a DNA structure-based model
In 2000, Zennou et al. reported that a cPPT mutant (the cPPT-D
mutant, Fig. 2) was impaired for spreading replication in primary
peripheral blood lymphocytes (PBLs) and MT4 cells (Zennou et al.,
2000). In single round assays the infectivity of HIV-1 vectors was
reduced, whether or not cells were growth arrested. The impair-
ment was not evidently a producer cell-determined restriction
since both 293T-produced and HeLa cell-produced virions in this
study showed the same effect. In target cells a relative decrease in
1- and 2-LTR circles was reported using calculations based on a
Southern blot assay that quantiﬁed various viral DNA species. The
authors concluded from this study that the DNA ﬂap itself is the
determinant of nuclear import of the HIV-1 pre-integration com-
plex in both dividing and non-dividing cells (Zennou et al., 2000).
This latter assumption – which became embodied in the name
that has been widely used since to describe the functionally
relevant entity (e.g., “ﬂap þ and − viruses”) – is worth careful
consideration because multiple studies that followed have focused
on this local cDNA structural peculiarity as the key determinant,
and also because the model proposed to solve the mechanism of
HIV-1 PIC nuclear import, which remains one of the most
important yet enduringly enigmatic problems in the ﬁeld
(Fassati, 2006; Shah and Aiken, 2010; Suzuki and Craigie, 2007).
Subsequent papers have provided data to support the Zennou
et al. ﬂap-nuclear import model, yet a gathering consensus
challenges its main conclusions strongly. To summarize a large
subsequent literature in the decade since the ﬂap model was
proposed, the cPPT-CTS (which is typically described as “the ﬂap”)
has been reported to enhance HIV-1 infection of both dividing and
non-dividing cells and also to enhance HIV-1-based lentiviral gene
therapy vector transduction in the brain and other cell types
(Baekelandt et al., 2002; Barry et al., 2001; Breckpot et al., 2003;
Charneau et al., 1992; Dardalhon et al., 2001; Follenzi et al., 2000;
Giannini et al., 2003; Hungnes et al., 1992; Manganini et al., 2002;
Nguyen et al., 2002; Park and Kay, 2001; Seppen et al., 2002;
Sirven et al., 2000; Van Maele et al., 2003; Zennou et al., 2000,
2001). Evidence for a role in nuclear import of the HIV-1 PIC has
been presented (Ao et al., 2004; Arhel et al., 2006a,2006b,2007; De
Rijck and Debyser, 2006; Follenzi et al., 2000; Iglesias et al., 2011;
Riviere et al., 2010; Sirven et al., 2000; Van Maele et al., 2003;
Zennou et al., 2000). In a number of studies, wild type and cPPT-
mutant viruses were visualized after entry using light and electron
microscopic methods (Arhel et al., 2006b,2007; Iglesias et al.,
2011; Zennou et al., 2000). These experiments have suggested that
cPPT-mutant PICs accumulate on the cytoplasmic side of the
nuclear envelope, with an interpretation that their progress was
speciﬁcally blocked at nuclear import. Additional speculations
have been that the plus strand discontinuity might relieve topo-
logical constraints and allow the viral cDNA to fold more com-
pactly as it traverses the pore (Zennou et al., 2000) or, more
recently, that formation of the ﬂap triggers capsid disassembly at
the nuclear pore (Arhel et al., 2007). At the same time, several
different signals in viral proteins (Matrix, Vpr, Integrase) were also
entertained as the principal determinant of HIV-1 PIC nuclear
import (for reviews see (Shah and Aiken, 2010; Suzuki and Craigie,
2007; Yamashita and Emerman, 2006)).
For the ﬂap DNA hypothesis, the enhanced viral replication
effects and the speciﬁc mechanistic assignment to PIC nuclearimport have each been questioned (Dvorin et al., 2002; Hu et al.,
2010; Limon et al., 2002; Marsden and Zack, 2007; Matreyek and
Engelman, 2011; Yamashita and Emerman, 2005). A comprehen-
sive analysis of different previously proposed nuclear import
determinants using HIV-1/MLV viral chimeras revealed no effect
of the cPPT-CTS on nuclear import (Yamashita and Emerman,
2005). This and other papers have led recently to the hypothesis
that capsid is in fact the principal determinant of HIV-1 PIC
nuclear import, albeit in complex ways that remain to be con-
solidated into a clear mechanism (Dismuke and Aiken, 2006; Lee
et al., 2010; Shah and Aiken, 2010; Yamashita and Emerman,
2004,2006,2009; Yamashita et al., 2007); see (Fassati, 2012) for a
recent review of the potential multiple roles of CA in early events.
The kinetic model: countering innate immune defenses that target
ssDNA
The full ramiﬁcations of retroviral cDNA transitions from single to
double-strandedness have only been recently appreciated. Focus on
this and other recent observations has led to an alterative model that,
in retrospect, may allow some but certainly not all of the previously
conﬂicting data sets to be reconciled. Here the cPPT story turns from
primarily considering PIC nuclear import to the broader terrain of
innate immunity. Two years after the proposal of the ﬂap-nuclear
import model, the vulnerability of the post-entry viral cDNA to host
defenses became a subject of intensive investigation when Sheehy
et al. (2002) identiﬁed the HIV-1 restriction factor targeted by the
viral protein Vif. It turned out to be a cytidine deaminase, APOBEC3G,
which incorporates into assembling particles and then catalyzes
deamination of viral minus strand cytidines (Bishop et al., 2004;
Harris et al., 2003; Malim, 2009; Mangeat et al., 2003; Sheehy et al.,
2002; Zhang et al., 2003).
Importantly, APOBEC3G deaminates ssDNA but not dsDNA
(Chelico et al., 2006; Yu et al., 2004). The net result when reverse
transcription completes is an accumulation of plus (coding) strand
G-A mutations, which are lethal when sufﬁciently pervasive.
However, there is also solid evidence for non-catalytic mechan-
isms that inhibit full cDNA formation by interfering with reverse
transcription (Bishop et al., 2008; Holmes et al., 2007; Newman
et al., 2005). Importantly then, this kind of restriction can act to
arrest the progress of the virus before and after nuclear entry.
HIV-1 Vif counters APOBEC3G by binding to it in virus producing
cells and connecting it to an E3 ubiquitin ligase complex comprised of
Cullin5, elongin B, elongin C and an unidentiﬁed E2 conjugating
enzyme, thereby inducing polyubiquination and proteasomal degra-
dation of the restriction factor (Conticello et al., 2003; Marin et al.,
2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu
et al., 2003). Therefore, the phenotype of Vif-minus HIV-1 depends on
the presence or absence of APOBEC3G in the virus producing cell
rather than the viral target cell (Gabuzda et al., 1992). An important
corollary of these discoveries is that single stranded DNA (ssDNA) is a
point of vulnerability for retroviruses.
A signiﬁcant clue to cPPT function can be found in sequencing
data that identiﬁed 5′-3′ gradients of G-to-A hypermutation in HIV-
1 genomes (Armitage et al., 2008; Kijak et al., 2008; Suspene et al.,
2006; Vartanian et al., 2002; Yu et al., 2004). Yu et al. (2004) detected
a 5′-3′ increase in G-A substitutions in Δvif HIV-1 and limited
editing immediately downstream of the 3′ LTR-proximal PPT. While
they did not sequence the central region of the virus, several studies,
some of which predate the discovery of APOBEC3 protein restriction,
identiﬁed a “twin peaks” effect, with relatively reduced G-A muta-
tion frequency downstream of both the 3′ LTR-proximal PPT and the
cPPT, and mutational maxima 5′ to these elements (Armitage et al.,
2008; Borman et al., 1995; Kijak et al., 2008; Suspene et al., 2006;
Vartanian et al., 2002). Wurtzer et al. (2006) reported that mutation
of the cPPT resulted in increased APOBEC3G-mediated G-A
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a Δvif virus. These mutation pattern biases were hypothesized to
reﬂect two factors: the 3-5′ processivity of APOBEC3G, which results
in preferential deamination toward the 5′ ends of single stranded
DNAs (Chelico et al., 2006), and a longer duration of the unduplexed
state for viral minus strand segments that lie further downstream
from plus strand initiation (Malim, 2009; Suspene et al., 2006; Yu
et al., 2004).
We then decided to construct and test a new set of cPPT-CTS (þ)
and (−) HIV-1 clones that were coding-neutral (Fig. 2, mcPPT, mCTS
and DM).With these, we noticed differences in viral replication in Vif-
permissive and non-permissive cells (Hu et al., 2010); see commen-
tary (Landau, 2010). The cPPT and the CTS were each mutated and
tested in the context of single cycle HIV-1 reporter viruses and
replicating HIV-1. Southern blotting veriﬁed that DNA ﬂap formation
was indeed disrupted. Nevertheless, single cycle infection was unaf-
fected in various target cells whether they were dividing or non-
dividing (Hu et al., 2010). Spreading HIV-1 infection was also normal
in most CD4þ human T cell lines, and cPPT and cPPTþCTS-mutant
viruses (the double mutant or DM virus) replicated equivalently to
wild type in nondividing cells, including macrophages. However,
spreading infection of DM HIV-1 was impaired in vif non-
permissive cells (HuT78, H9, primary human PBMCs), suggesting
APOBEC3G restriction was at play. Single cycle infections conﬁrmed
that vif-intact cPPT-mutant or DM HIV-1 is restricted by producer cell
APOBEC3G/F. Combining Δvif and cPPT-CTS mutations increased
APOBEC3G restriction synergistically. Moreover, RNAi knockdown of
APOBEC3G in HuT78 cells released the block to DM virus replication.
The DM virus also accrued markedly increased APOBEC3G-mediated
G-A hypermutation compared to wild-type HIV-1 (a full log10 in the
0.36 kb downstream of the mutant cPPT).
Considering all of these results in the context of the prior HIV-1
genome sequencing data, Hu et al. (2010) proposed a kinetic model in
which the ﬂapped DNA structure is not the consequential outcome.Fig. 4. Kinetic model of cPPT defense against minus strand attack. The ﬁgure summarizes t
with location of the cPPT-CTS at the center of the genome. The ﬂap model posits that the
recent elaboration, triggers uncoating (Arhel et al., 2007). The kinetic model predicts that
is protective against host defenses that target single stranded DNA, including but perhap
considered an epiphenomenon rather than the key functional determinant. Importantly,
kinetic advantages to central plus strand initiation if faster completion of double-strande
in other ways.The salient functional feature is instead central plus strand initiation,
which is proposed to function as a viral second line of defense against
ssDNA editing by APOBEC3 proteins that survive producer cell
degradation by Vif and perhaps against other restrictions that target
single stranded viral DNA or act to delay plus strand synthesis. The
model is illustrated in Fig. 4, where it is contrasted with the DNA ﬂap-
nuclear import model. The process that eventuates in the ﬂap rather
than the ﬂapped DNA structure itself is emphasized.
A methodologically innovative analysis of the step by step kinetics
of HIV-1 reverse transcription is consistent with the kinetic model.
Using strand-speciﬁc PCR, Thomas et al. (2007) found that Dþ strand
synthesis appears to occur before Uþ stand synthesis. In fact, Dþ
strand synthesis even appears to complete before the minus strand
synthesis reaches the primer binding site, and thus even before the
second strand transfer that enables the Uþ strand synthesis to start.
Considering this, as illustrated in Fig. 1A,B, step 5, note that a
retrovirus reverse transcribing without central plus strand initiation
is predicted to require a longer duration to complete the plus strand.
Fig. 1B could also be imagined to have a step 3b, which would be
identical to step 4 but with no Uþ strand. Nevertheless, these
considerations are not incompatible with the ﬂap model in the sense
that the formation of the displaced DNA segment is likely to be one of
the last events to occur in the sequence; as such it can be
hypothesized to be a trigger for the next phase of the life cycle
(Arhel et al., 2007).
Several studies have now shown that cPPT-mutant viruses undergo
spreading replication to substantial but variable extents in macro-
phages and PBMCs (Dvorin et al., 2002; Hu et al., 2010; Limon et al.,
2002). This is consistent with observations that APOBEC3G and A3F
levels are low in macrophages in the absence of immune effector
cytokines such as interferon-alpha, which induce their expression
(Koning et al., 2009). Type III interferon also up-regulates APOBEC3G
expression in macrophages (Hou et al., 2009). Sarkis et al. (2006)
reported that APOBEC3Gwas up-regulated by interferon-alpha in bothhe two models discussed in this review for HIV-1 cPPT function. Both are consistent
ﬂap itself either engages the nuclear import apparatus (Zennou et al., 2000) or in a
earlier conversion to double-strandededness in the downstream half of the genome
s not limited to A3 proteins (Hu et al., 2010). Here, the ﬂapped DNA structure itself is
a role in APOBEC3 protein counter-defense or sensor evasion does not exclude other
dness acts to stabilize the viral complex or license its progress to the integrated state
E. Poeschla / Virology 441 (2013) 1–116hepatocytes and macrophages, but not in T cells or 293T cells, with
macrophage levels being strongly donor-dependent. Vif may be
adequate to prevent virion APOBEC3G incorporation in macrophages
that are not induced.
Prior discrepancies between results in primary cells could in
part reﬂect donor and cell type-dependent APOBEC3G expression
variability. For example, even Δvif HIV-1 has been reported to
undergo spreading replication in macrophages, at an attenuated
level (Chowdhury et al., 1996). It is possible that heterogeneity in
macrophage activation state related to methods of isolation and
culture are also involved (Sica and Mantovani, 2012). In human
CD4þ T cell lines, APOBEC3G/F may exert low levels of selection
pressure for Vif and cPPT-CTS maintenance since we can detect
small amounts of APOBEC3G protein with optimized immunoblot-
ting even in some vif-permissive lines (SupT1, MT4, Jurkat, A3.01,
CEM-SS) generally regarded as negative for APOBEC3G expression
(Saenz and Poeschla, unpublished data). In regard to the choice of
cells and cell lines, it will be helpful in the future to use cells that
are closer to the real situation, such as CD4þ human T cell lines
and primary CD4þ cells. HeLa-CD4 (HeLa-P4) cells have been used
frequently for cPPT-CTS work but they may be a suboptimal for
early event studies, and certainly for spreading infection studies.Limitations of 2-LTR circle and “late” DNA assays
In almost all studies that have assigned “the ﬂap” a role in PIC
nuclear import, 2-LTR circle PCR assays, and sometimes a Southern
blot detection of 1-LTR circular DNAs, have been used to gauge
nuclear import. For example, Van Maele showed that all DNA forms
measured (total, 2-LTR circles and integrated) peaked higher when
vectors contained the cPPT-CTS (VanMaele et al., 2003). Other studies
also observed this higher accumulation of circles (De Rijck and
Debyser, 2006). These data could certainly be consistent with a
speciﬁc nuclear import function but the case is not yet clear. While
the 2-LTR circle assay has been important as the only convenient way
to distinguish between unintegrated cytoplasmic and nuclear retro-
viral DNA, it’s limitations are substantial. Using it as a surrogate for
nuclear import, it is easy to assign an impact on the viral life cycle to
nuclear import per se, whenwhat may really be recorded is an earlier
bottleneck or bottlenecks, i.e., a failure to mature the incoming virion
to a pre-nuclear stage that permits the chain of downstream events to
proceed, including nuclear import. This is particularly the case if PCR-
based assays for “late DNA” are relied on to assess completion of
reverse transcription. The latter generally only assess whether the
second strand transfer and some portion of Uþ strand synthesis has
occurred and do not address at all whether the region covered by the
distal Dþ strand has become double-stranded. Thus a diminution in
2-LTR circles in the face of normal levels of “late DNA” and total DNA
does not establish whether a fully dsDNA viral genome with
integrase-processed 3′ termini has arrived at the nucleopore but
lacks the ability to traverse it.
A further problem with this assay is its complex kinetics: circle
formation, a dead-end diversion reaction catalyzed by nuclear
enzymes, is affected by a variety of processes, such as impaired
integration (which drives circle formation, probably by causing a
build-up of linear substrate), metabolism (decreased circles), and
presumably other nuclear factors such as the activities of nuclear
enzymes that ligate the two viral ends. Therefore, a decrease in 2-
LTR circles is not by itself a reliable indicator of a block to PIC
nuclear translocation.
The cPPT-CTS is located in the integrase reading frame
An additional confounding problem persisted for over a decade
but is readily remedied. In the study of Hu et al. (2010), entirelysynonymous mutations (eight and seven nucleotide changes in the
cPPT and CTS respectively) were chosen to securely inactivate cPPT
use while also avoiding a persistent ambiguity from previous studies.
Most studies have employed the cPPT-D mutant constructed by
Zennou et al. (2000) which contains a lysine-to-arginine change at
position 188 in the integrase protein (Ao et al., 2004; Arhel et al.,
2006a; De Rijck and Debyser, 2006; Dvorin et al., 2002; Limon et al.,
2002; Marsden and Zack, 2007; Sirven et al., 2000; Zennou et al.,
2000). K188 is part of the highly conserved K186R187K188 motif that
participates in the integrase dimer interface (Wang et al., 2001).
Although this change was conservative from the standpoint of amino
acid properties, K188R is not likely to be neutral as it is rarely found
in subtype B sequence databases and in is not present in HIV-1
infectious molecular clones. Single amino acid integrase mutants are
notorious for producing complex (“class II”) effects not just on
integration per se, but throughout the retroviral life cycle, including
during viral assembly, reverse transcription, and integration
(Engelman et al., 1995). It is also unknown whether the rare
occurrences of this mutation in database sequences correspond to
ﬁt integrase proteins or are matched by unknown compensatory
second site mutations in other regions of pol. Finally, proper experi-
mental use of the cPPT-D mutant requires matched K188R control
viruses (e.g., the cPPT-AG mutant (Zennou et al., 2000) shown in
Fig. 2) which has rarely been followed in practice and which yields an
unnecessary complication to experimental work and interpretation.
Further confusing matters, this “control virus” mutation itself also
changes the cPPT sequence. At a minimum, future analyses of the
cPPT-CTS will beneﬁt from using the mcPPTor DMmutants (Hu et al.,
2010), and the cPPT-D mutant should not be used.
Despite these considerations however, for over a decade the cPPT
literature has contained contradictory data that are not readily
reconciled by considering the speciﬁc mutation sets, cell types or
assays employed. For example, some of the data in the most recent
paper, (Iglesias et al. (2011), were generated with the cPPT-D mutant
but some utilized combined cPPT-CTS mutations that were fully
synonymous in integrase. These authors also obtained and studied
the viruses of Hu et al. (2010) and reached rather divergent
conclusions with them, ﬁnding strong single cycle phenotypes for
viruses produced in 293T cells. It has been suggested that a source of
some discrepant outcomes in such experiments may be viral
inoculum-dependence (or saturability) of “ﬂap” phenotypes (De
Rijck and Debyser, 2006; Iglesias et al., 2011). However, in other
experiments minimal of absent cPPT(-) virus phenotypes were
consistent over several logs of challenge virus input; recent examples
include Hu et al. (2010), Matreyek and Engelman (2011). As is
discussed further below, we can conjecture that restriction mechan-
isms that are variably inducible in cells or that may have threshold
effects (such as variable dNTP levels) might help to explain some of
these discrepancies in the future.Questions for future research
Uncoating and RT kinetics
Reverse transcription and uncoating are connected processes
(Arﬁ et al., 2009; Hulme et al., 2011). Mature lentiviral capsid cores
consist of a uniquely shaped fullerene cone in which some 1500
capsid monomers form a lattice consisting of approximately 250
capsid hexameric rings, with 12 interspersed capsid pentamers
reﬁning the conical geometry (Ganser-Pornillos et al., 2007;
Pornillos et al., 2009,2011). Cores also appear to be ﬁnely tuned
for optimal stability, such that mutations that either augment or
diminish core stability have drastic effects on infectivity (Forshey
et al., 2002). Depending on the cellular environment, dNTP levels
and other factors, optimal uncoating of the conical lentiviral core
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reverse transcription kinetics consequent to cPPT-primed central
plus strand initiation. In other words, the capsid core and reverse
transcription particularities of lentiviruses have co-evolved. Where
in the traverse of the cytoplasm uncoating initiates and completes
are controversial, as well as inherently challenging to study. There
is evidence that uncoating occurs in the cytoplasm as early as 30–
60 min post-infection (Fassati and Goff, 1999, 2001; Hulme et al.,
2011; Perez-Caballero et al., 2005). While much evidence indicates
that capsid is shed from the PIC prior to nuclear import (Farnet
and Haseltine, 1991; Fassati and Goff, 2001; Miller et al., 1997)
(Bukrinsky et al., 1993; McDonald et al., 2002), it remains unclear
how much is lost fractionally prior to nuclear import and some
data suggest that full dispersal of capsid only occurs in the nucleus
(Zhou et al., 2011). Expression of dominantly interfering forms of
the integrase cofactor LEDGF indicated that prior to nuclear
import, uncoating proceeds to the point where PIC integrase
becomes accessible to interaction with cytoplasmic proteins
(Meehan et al., 2011). However, uncoating has cell type-
dependent features; HeLa cells have often been used for cPPT
mutant and other PIC nuclear import studies, but these highly
passaged cervical carcinoma cells may be distinct outliers in many
ways (Landry, 2013; Maher, 2012; van Valen, 1991), including their
apparent support of especially rapid reverse transcription (Arﬁ
et al., 2009). Schaller et al. (2011) have proposed that RanBP2/
Nup358 may act at the nucleopore to facilitate uncoating. Simi-
larly, Arhel et al. (2007) have reported that inhibiting reverse
transcription either with nevirapine to block it entirely or with
only cPPT mutations resulted in the accumulation of conical capsid
cores at the outer nuclear membrane. In their proposed model, it is
the ﬂapped DNA itself that triggers uncoating as the virus engages
the nucleopore (Arhel et al., 2007). Here again, however, the
ﬂapped DNA versus the process that produces it becomes the
question. It is equally plausible that completed synthesis of plus
strands with correct kinetics (Figs. 1 and 4) is needed for optimal
core maturation, uncoating and nucleopore transit to unfold.Cellular nucleic acid sensors
The threat of genome invasion by reverse-transcribing viruses
is pervasive enough that it will be unsurprising if additional innate
immunity mechanisms besides APOBEC3 proteins are found to
sense and target the nucleic acids of the reverse transcription
complex, which at various points in the process include ssDNA,
DNA/RNA hybrids, and dsDNA. Mammalian cells sense pathogen-
associated molecular patterns (PAMPs) with several broad classes
of nucleic acid sensors that target particular RNA or DNA species
that are not normally found in cells or particular locations in cells
[for recent reviews see (Ishii et al., 2008; Sharma and Fitzgerald,
2011; Wilkins and Gale, 2010)]. The innate immune system is
primed to use pattern recognition receptors to recognize viral
nucleic acids in two general types: incoming genomes or the more
abundant nucleic acids that arise during viral replication. Two
main systems that correspond to these activities are the cytosolic
RNA helicases (e.g., RIG-I, MDA5, LGP2), which are triggered by
replicating viral RNAs (RNA virus-generated dsRNA is a major
activator) and the endosomal Toll-like receptors (TLR3, TLR7, TLR8
and TLR9), which sense incoming viral nucleic acids (Barbalat
et al., 2011). Engagement of either can activate proinﬂammatory
cytokine and chemokine networks, including type I interferon
signaling. There are also cytoplasmic DNA sensor systems, which
are less well understood, such as DAI/AIM-2 (Hornung et al.,
2009), RNA polymerase III, LRRFIP1, IFI16, and DExD/H box
helicases DHX9 and DHX36 (Barber, 2011a,2011b; Sharma and
Fitzgerald, 2011).As opposed to other RNA viruses and some DNA viruses, clear
evidence for triggering of innate immunity systems by pre-
integration retroviral nucleic acid species has been harder to come
by, but some recent studies have been provocative (Doitsh et al., 2010;
Iwasaki, 2012; Yan et al., 2010). There is accumulating evidence that
mammalian cells have a cytoplasmic DNA sensor or sensors capable
of detecting retroviral DNA. For example, the main cytosolic 5′-3′
exonuclease, TREX1 (Stetson et al., 2008), has been reported to digest
excess HIV-1 cDNA that would otherwise trigger an as yet unidenti-
ﬁed DNA sensor (Yan et al., 2010). Sensing activates interferon
expression via a pathway dependent on the kinase TBK1, the adapter
STING (Ishikawa et al., 2009) and the interferon-regulatory factor IRF3
(Yan et al., 2010). Further evidence for immune activation by HIV-1
cDNA was seen in a human lymphoid tissue (tonsil) culture system
(Doitsh et al., 2010). Abortive infection leading to partial reverse
transcripts was much more common than completed integration in
resting CD4þ T cells. While the DNA sensing mechanism involved is
as yet unclear, the accumulation of partial reverse transcripts in these
non-productively infected T cells triggered proapoptotic and proin-
ﬂammatory responses and extensive cell death (Doitsh et al., 2010).
Mutations in TREX1 are one cause of the rare Aicardi-Goutières
(AGS) autoimmunity syndrome and chilblain lupus, in which the
putative DNA sensor becomes over-activated (Crow et al., 2006;
Rigby et al., 2008; Stetson et al., 2008). AGS patients suffer from a
multi-system inﬂammatory disease with manifestations that
resemble chronic viral infection. They can have several genetic
defects, including mutations in another host cell protein, SAMHD1
(Rice et al., 2009).
SAMHD1 restricts HIV-1 in cells of the myleoid lineage (Hrecka
et al., 2011; Laguette et al., 2011). It appears to act by reducing the
cellular levels of dNTPs available for reverse transcription
(Goldstone et al., 2011; Lahouassa et al., 2012). Recently SAMHD1
3′ to 5′ exonuclease activity against single stranded DNAs and
RNAs was also reported (Beloglazova et al., 2013). The primate
lentiviral accessory protein Vpx, which is normally conﬁned to the
HIV-2/SIVsm/SIVrcm/SIVmac lineages, targets SAMHD1 for protea-
somal degradation (Hrecka et al., 2011; Laguette et al., 2011).
When Vpx is provided to HIV-1 artiﬁcially, infection of otherwise
refractory dendritic cells occurs (Goujon et al., 2006) and an
antiviral type I interferon response and T cell activation ensues
(Manel et al., 2010). By dispensing with a Vpx protein, HIV-1 and
its immediate ancestors may avoid the dendritic cell compart-
ment. While SAMHD1 itself is not considered a sensor, the
restriction in these key antigen presenting cell types may limit
sensing by other mechanisms (restriction beneﬁts the virus in this
view). On the other hand, since it is increasingly clear that dNTPs
may be rate limiting for lentiviruses in other important target cells
(Baldauf et al., 2012), initiating plus strand synthesis from more
than one locus could pose advantages for the virus in other
contexts.
Prior to uncoating-mediated nucleic acid exposure, the retro-
viral capsid may also serve as a PAMP, in different ways (Manel
and Littman, 2011). One model augments more direct TRIM5
restriction mechanisms by proposing a post-entry TRIM5-insti-
gated signaling cascade in macrophages (Pertel et al., 2011).
Another posits that newly synthesized capsid protein with bound
CypA activates a sensor in dendritic cells (DCs) (Manel et al., 2010).
A corollary hypothesis is that since HIV-1 does not encode Vpx, it
largely evades this human DC sensor, which might contribute to its
systemic spread and pathogenesis (Manel et al., 2010). A number
of signal transduction pathways have been implicated (Manel
et al., 2010; Pertel et al., 2011; Yan et al., 2010). In general, they
converge on IRF3, which is required for ifnb1 transcription.
This area – cytoplasmic sensing and targeting of the protein
and nucleic acid PAMPs of incoming retroviruses – deserves
further research attention in the near future.
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lentiviral transfer vectors
An important riddle that remains concerns the kinds of lentiviral
vectors used in gene therapy. In retrospect, some of the controversy
stems from discrepancies between studies that focused on spreading
HIV-1 infection or HIV-1 reporter viruses and those that used
minimal, trans-packaged HIV-1-based lentiviral vectors. Why is this
distinction signiﬁcant? In our hands and in the hands of many other
laboratories, trans-packaged minimal HIV-1 transfer vectors that
contain the cPPT-CTS element routinely perform better – in virtually
all experimental settings – than cPPT-CTS-lacking vectors. Although
there are instances in which the opposite has been reported (De Rijck
and Debyser, 2006), particle for particle, they reproducibly generate
higher titers and better percent transduction. This is generally the
case whether or not the targets are cell lines or primary cells, dividing
or non-dividing, or transduced in vitro or in vivo (Baekelandt et al.,
2002; Barry et al., 2001; Breckpot et al., 2003; Dardalhon et al., 2001;
De Rijck et al., 2005; Follenzi et al., 2000; Giannini et al., 2003;
Hungnes et al., 1992; Manganini et al., 2002; Nguyen et al., 2002; Park
and Kay, 2001; Seppen et al., 2002; Sirven et al., 2000; Van Maele
et al., 2003; Zennou et al., 2000,2001). The difference between cPPT-
CTS (þ) and (−) HIV-1 vectors has varied, but is generally on the
order of 0.5–1.0 logs depending on MOI and the particular end-point
measured. In lentiviral vectors, then, it is clear that the cPPT-CTS
works to augment transduction efﬁciency. This underscores the
importance of research on how it works. Moreover, in most of these
reports, the vectors were produced in 293T cells (Follenzi et al., 2000),
which are generally agreed to lack signiﬁcant APOBEC3G/F expression
and so while ssDNA vulnerability could still be at play, their super-
iority cannot be explained by invoking APOBEC3G/F proteins per se.
Therefore, this transfer vector effect constitutes a signiﬁcant
difference with the full-length virus itself. When HIV-1 or pseudo-
typed near full-length HIV-1 reporter viruses are produced in 293T
cells they generally do not obtain the same boost in single cycle
infectivity compared to their cPPT(-) versions (Dvorin et al., 2002; Hu
et al., 2010; Limon et al., 2002; Marsden and Zack, 2007; Matreyek
and Engelman, 2011; Yamashita and Emerman, 2005). When inter-
rogated for dependence on Nup153, a nucleoporin implicated in PIC
nuclear import, no signiﬁcant difference between cPPT(þ) and (−)
reporter viruses was seen (Matreyek and Engelman, 2011).
Unless the “DNA triple stranded ﬂap structure mediates nuclear
import” model is correct, the most likely explanation for this
difference is kinetic and/or evasion of antiviral sensor-effector
systems but the full explanations are not clear. An important
aspect to consider is that lentiviral transfer vectors used in gene
therapy have highly “abnormal” genomes compared to an actual
lentivirus. This is quite purposeful, since an over-riding goal of safe
lentivector design is to strip the transfer vector of everything but
the minimal cis-acting elements needed for RNA export, encapsi-
dation, reverse transcription and integration, and also to load it
with a therapeutic or marker gene payload that is non-lentiviral in
origin and designed for robust, Tat- and Rev-independent expres-
sion in the target. As such, the net nucleotide composition
(extremely A-rich in all lentiviruses, predominantly due to third
codon position bias, and often GC-rich in transgene cassettes), the
folded gRNA structure, the reverse transcribed linear cDNA struc-
ture, the way the nucleic acids occupy the virion capsid, how they
are bound to other virion components, and how they become
exposed to cellular constituents may well vary considerably from
the wild-type virus. In other words, trans-packaged minimal
marker gene transfer vectors that lack almost all of the HIV-1
genome may be vulnerable in ways that the real genome is not,
and completing the double-stranded state more rapidly may be
critical for them. The putative effector antiviral mechanisms would
not be the known producer cell-determined APOBEC3 proteinssince they are not expressed in 293T cells and there is not to my
knowledge evidence that they are induced during lentiviral vector
production. Future experiments that focus on this aspect may yield
unexpected insights. It will be equally important in the future to
explicitly consider the transfer vector versus virus distinction
when experiments are designed and data are interpreted.
Other retroviruses
Central plus strand synthesis is apparently universal in lenti-
viruses. cPPT sequences have been identiﬁed in all known primate
and non-primate lentiviruses (Fig. 3). Moreover, the location is
also curiously highly conserved: for example, while the mapped
cPPTs of all the different lentiviruses act in cis, they all encode
essentially the same motif in integrase (Fig. 3). The Visna, FIV and
EIAV cPPT elements have each been shown to prime plus strand
synthesis and for FIV and EIAV the CTS has also been determined
by 3′ RACE mapping (Stetor et al., 1999; Whitwam et al., 2001). The
FIV cPPT is distinctive in being signiﬁcantly divergent in sequence
from its 3′ counterpart and in containing one, and in some proviral
sequences, two pyrimidines.
However, evidence for a speciﬁc function in retroelement life
cycles (other than plus strand priming and central gap/ﬂap formation)
has so far only been reported for HIV-1 (Heyman et al., 1995,2003;
Kupiec et al., 1988; Stetor et al., 1999; Tobaly-Tapiero et al., 1991;
Whitwam et al., 2001,1999). The FIV cPPT-CTS element has not been
shown to confer substantial increases in viral or vector titer (our
unpublished data). In the case of EIAV, one study that examined this
variable also did not see appreciable differences between vectors that
did or did not have the cPPT-CTS (O’Rourke et al., 2005). cPPT-mutant
Ty1 does not display dramatic attenuation suggesting that the value
to the retrotransposon is more subtly context-dependent (Heyman
et al., 2003).These examples provide interesting counterpoints to HIV-
1, but the experimental record for these other viruses is too limited at
present to draw ﬁrm conclusions.Avoiding assumptions
The kinetic model returns focus to what the cPPT ﬁrst and
foremost is: a reverse transcription primer (Hu et al., 2010).
Descriptors such as “ﬂap (þ) and (−)” seem best avoided in favor
of “cPPT (þ) and (−)” in most instances unless the experiments in
question speciﬁcally concern the DNA structure at the strand
displacement. The reason is that this term perpetuates an assump-
tion for which there has been little direct evidence: that one
transient outcome of the reverse transcription process – the
centrally located strand displacement – is the key factor in the
viral life cycle rather than the ﬂap-generating process itself. It now
seems equally plausible that central plus strand initiation imparts
its functional signiﬁcance from the very start of the process, by
increasing the probability of generating the completed dsDNA that
is an absolute pre-requisite to 3′ processing and integration.
The assumption at the heart of the structural model in any case
remains very difﬁcult to prove in the absence of ways to generate a
bona ﬁde DNA ﬂap in the PIC while avoiding the kinetic con-
sequences of central initiation. There have been attempts to get at
this by positioning the cPPT-CTS element eccentrically in HIV-1
transfer vectors but these maneuvers in general produced effects
that support the case for a kinetic model (De Rijck et al., 2005). In
this study, although the presence of any cPPT-CTS element yielded
higher titer vectors, positioning the element 5′ of the center
produced higher infectivity in most cell targets while more 3′
placement reduced it. For example, versus cPPT-minus vectors,
there were 19- 12- and 6-fold more 293T cell integrants for vectors
with 5′, central and 3′-postioned elements respectively.
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describe viruses without implicitly ignoring the whole process of
reverse transcription that precedes ﬂap formation. Viruses and
vectors being tested are preferably named neutrally, as “cPPT (þ)”
and “cPPT (−)” rather than with the assumption-loaded “ﬂap (þ)”
and “ﬂap (−).” These terms apply equally well to the structural and
kinetic models.Concluding remarks
The insistent threat of genome invasion by retroelements has
resulted in antagonistic co-evolution with their hosts. Beginning
with Visna virus experiments in the pre-HIV era, research on this
once obscure variation of the standard reverse transcription
mechanism has turned out to intersect with interesting, current
questions about cellular antiviral defenses. Central plus strand
initiation has been evolved by diverse retroelements, so that its
virological advantages very likely encompass more than nuclear
translocation. Central plus strand synthesis minimizes the pre-
sence of vulnerable unpaired minus strand DNA in the lentiviral
reverse transcription complex (Figs. 1 and 4). The sometimes
contradictory literature may reﬂect that the extent to which a
cPPT-CTS element effect is observed in an experiment may depend
on factors that include APOBEC3 proteins, perhaps other antiviral
mechanisms that target single stranded DNA or affect uncoating
kinetics, and dNTP levels. The nature of the genome in the particle
– bona ﬁde virus or highly artiﬁcial vector – may also inﬂuence
results. It is exciting that the relative black box of the interval
comprised by capsid disassembly and nuclear import is beginning
to yield to close examination of relationships between uncoating,
reverse transcription, species-speciﬁc restriction factors, dNTP
levels, various nucleoporins and nucleocytoplasmic transport
receptors. Central plus strand initiation and other viral properties
that inﬂuence reverse transcription kinetics, uncoating, and the
vulnerability of viral nucleic acid to cellular sensor and effector
mechanisms are important pieces of the puzzle.Acknowledgments
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